Bulletin
Investor Alert

Market Pulse Archives

Nov. 12, 2019, 10:40 a.m. EST

Kadmon biopharma shares rise on interim trial results

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Kadmon Holdings Inc. (KDMN)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of Kadmon Holdings /zigman2/quotes/208978354/composite KDMN -0.21% are up about 10% after the New York-based biopharmaceutical company said its treatment for certain patients with chronic graft-versus-host disease met the primary endpoint in a trial. Chronic graft-versus-host disease is a rare condition that can occur after a transplant. Kadmon said it expects to file the experimental therapy with the U.S. Food and Drug Administration next year. Its stock is up 58.65% year-to-date, while the S&P 500 /zigman2/quotes/210599714/realtime SPX +0.0073% has gained 23%.

/zigman2/quotes/208978354/composite
US : U.S.: NYSE
$ 4.73
-0.01 -0.21%
Volume: 1.94M
Dec. 13, 2019 6:30p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$613.44 million
Rev. per Employee
$12,035
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
3,168.80
+0.23 +0.0073%
Volume: 1.96B
Dec. 13, 2019 5:14p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.